BioSpace News Archive

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria, announced that it has completed enrollment in its Oxabact ePHex phase III study.

Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002)

Genetic Technologies Limited announced the closing of the previously announced registered direct offering of 1,028,574 American Depositary Shares, each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.

Axonics Modulation Technologies, Inc. announced the submission of a premarket approval supplement to the U.S. Food & Drug Administration for the purpose of gaining full-body magnetic resonance imaging conditional labeling for 3.0T MRI scans..

Application is Supported by Data from Pivotal Phase 3 Study for the Treatment of Deep Partial-Thickness Thermal Burns

SeaSpine Holdings Corporation announced preliminary financial results for the first quarter of 2020 and a business update on the proactive steps it is taking in response to the global COVID-19 pandemic.

Plus Therapeutics, Inc., announced that it is donating personal protective equipment to San Diego’s Scripps Health for distribution to its front-line doctors, nurses and other health-care practitioners caring for patients affected by the COVID-19 pandemic.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), the leading developer of spider silk based fibers, announces that Kim Thompson, the Company’s CEO and Founder, has accepted an invitation to speak at this year’s SynBio Markets conference to be held in Amsterdam, Netherlands beginning November 3rd.

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the COVID-19 Transplant Registry (C19TxR.org).

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM902, an immuno-oncology therapeutic antibody targeting TIGIT, in patients with advanced malignancies.